Journal: Frontiers in Immunology

Article Title: The CXCL9/SPP1 polarity axis in tumor-associated macrophages: immunoregulatory and prognostic significance in non-small cell lung cancer

doi: 10.3389/fimmu.2026.1763652

Figure Lengend Snippet: Validation of CXCL9 + and SPP1 + macrophage expression and polarization characteristics in lung cancer tissues. (A) Representative mIF staining for CXCL9+ TAMs and SPP1+ TAMs in lung tissue sections from the normal and LUAD tumor groups. DAPI (blue), CD68 (red), CXCL9 (yellow), SPP1 (green) are shown, along with individual and merged channels. (n = 3 per group). Scale bar, 20 μm. (B) Representative mIF staining of CXCL9+ TAMs (yellow) and SPP1+ TAMs (green) in lung tissue sections from the normal and LUAD tumor groups (n = 3 per group). Scale bar, 20 μm. (C) qRT-PCR validation of macrophage polarization. The M1 group showed high expression of Cxcl9 and iNOS, while the M2 group showed high expression of Spp1 and Arg1. Asterisks indicate statistically significant differences (*p < 0.05).

Article Snippet: Following another stripping step, the third round was performed using mouse anti-human CD68 monoclonal antibody (1:50000, Servicebio, Cat# GB153150 ) with HRP-conjugated goat anti-mouse secondary antibody (ready-to-use, Servicebio, Cat# G1301), and signal was developed using iF555-Tyramide (1:500, Servicebio, Cat# G1233).

Techniques: Biomarker Discovery, Expressing, Staining, Quantitative RT-PCR

Journal: Cancer Research Communications

Article Title: Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

doi: 10.1158/2767-9764.CRC-25-0123

Figure Lengend Snippet: Graphs depicting the density of macrophage subsets pre- and posttreatment with TRK-950. Tumor specimens obtained with core-needle biopsies at the screening and C1D22 time points were subjected to multi-immunofluorescence to detect macrophage infiltrates. Quantitative analyses were performed on digital images of CD68 and CD163 staining. A, total CD68 + cells; ( B ) CD68 + /CD163 − subsets; ( C ) CD68 + /CD163 + subsets. Error bars indicate SD. C1D22, cycle 1 day 22; SCR, screening.

Article Snippet: After antigen retrieval (36 minutes at 95°C, pH 8.4), 4-μm-thick sections of tumor specimens obtained from core-needle biopsies at the screening and C1D22 time points were stained with mouse monoclonal anti-human CD68 (IgG2b, clone 298807, R&D Systems) and mouse monoclonal anti-human CD163 (IgG1, clone 10D6, Leica Biosystems) and then incubated with AF647 goat anti-mouse IgG2b and AF488 goat anti-mouse IgG1 (both from Invitrogen).

Techniques: Immunofluorescence, Staining

Journal: Arthritis Research & Therapy

Article Title: Investigation of GPM6B as a novel therapeutic target in Osteoarthritis

doi: 10.1186/s13075-024-03430-6

Figure Lengend Snippet: GPM6B expression in the synovium of patients with OA. ( A ) Double immunofluorescence staining of CD68/GPM6B (upper panel) and vimentin/GPM6B (lower panel). CD68 and vimentin are markers for MLS and FLS, respectively. Negative control (NC), without primary antibodies; scale bars: 75 μm. ( B ) Immunofluorescence staining of GPM6B in primary FLS isolated from synovial tissues of female and male patients with OA; scale bars: 150 μm. ( C ) qPCR analysis of GPM6B levels in primary FLS isolated from synovial tissues of female and male patients with OA. Data are presented as the mean ± standard error, ** P < 0.01

Article Snippet: The following primary antibodies were used: mouse anti-human vimentin antibody (Boster Biological Technology; Wuhan, China), mouse anti-human CD68 antibody (Boster), and rabbit anti-human GPM6B antibody (Abcam; Cambridge, MA, USA).

Techniques: Expressing, Double Immunofluorescence Staining, Negative Control, Immunofluorescence, Staining, Isolation

Journal: Arthritis Research & Therapy

Article Title: Investigation of GPM6B as a novel therapeutic target in Osteoarthritis

doi: 10.1186/s13075-024-03430-6

Figure Lengend Snippet: GPM6B expression in the synovium of patients with OA. ( A ) Double immunofluorescence staining of CD68/GPM6B (upper panel) and vimentin/GPM6B (lower panel). CD68 and vimentin are markers for MLS and FLS, respectively. Negative control (NC), without primary antibodies; scale bars: 75 μm. ( B ) Immunofluorescence staining of GPM6B in primary FLS isolated from synovial tissues of female and male patients with OA; scale bars: 150 μm. ( C ) qPCR analysis of GPM6B levels in primary FLS isolated from synovial tissues of female and male patients with OA. Data are presented as the mean ± standard error, ** P < 0.01

Article Snippet: The following primary antibodies were used: mouse anti-human vimentin antibody (Boster Biological Technology; Wuhan, China), mouse anti-human CD68 antibody (Boster), and rabbit anti-human GPM6B antibody (Abcam; Cambridge, MA, USA).

Techniques: Expressing, Double Immunofluorescence Staining, Negative Control, Immunofluorescence, Staining, Isolation